All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of the pivotal Phase 3 studies but resolved prior to the Visit 1 date for this extension study.

All SAEs were deemed unrelated to treatment with tapinarof cream, 1%.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of the pivotal Phase 3 studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE.

All SAEs were deemed unrelated to treatment with tapinarof cream, 1%.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in chemistry and hematology parameters for individual subjects were assessed for clinical relevance. The number of subjects with clinically significant changes from baseline in laboratory values was assessed for clinical relevance.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the median time for subjects entering with a PGA = 0 to first worsening (PGA ≥ 2) while off therapy during this extension study.

The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued treatment with tapinarof until they achieved a PGA = 0, at which time treatment was discontinued and subjects were monitored for remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the number of subjects who entered the extension study with a PGA ≥ 1 and achieved complete disease clearance (PGA=0) while on therapy during this extension study.

The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued treatment with tapinarof until they achieved a PGA = 0, at which time treatment was discontinued and subjects were monitored for remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved.

This outcome measure assesses the number of these subjects who entered the study with a PGA≥ 2 and achieved a PGA of 0 or 1 (clear or almost clear) while on therapy during this extension study.

The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. This outcome measure assesses the number of these subjects entering the study with a PGA= 0 who experienced worsening (PGA ≥ 2) while off therapy at least once during this extension study.

The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy.

BSA affected was estimated by the handprint method, where the full palmar hand of the subject represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints (hp) with percentage [Head and neck = 10% (10 hp), upper extremities = 20% (20 hp), Trunk (including axillae and groin) = 30% (30 hp), lower extremities (including buttocks) = 40% (40 hp)]. The total %BSA involved was estimated = % involvement

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy.

BSA affected was estimated by the handprint method, where the full palmar hand of the subject represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints (hp) with percentage [Head and neck = 10% (10 hp), upper extremities = 20% (20 hp), Trunk (including axillae and groin) = 30% (30 hp), lower extremities (including buttocks) = 40% (40 hp)]. The total %BSA involved was estimated = % involvement

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued tapinarof until they achieved a PGA = 0, at which time treatment was discontinued. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved.

Mean duration (days) of treatment episode = time (days) from date of each PGA ≥ 2 (or PGA ≥ 1 for the first episode) to 1 day before each subsequent PGA = 0.

The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in PASI score in all subjects, including those on and those off therapy.

The PASI scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-<10%), 2 = (10-<30%), 3 = (30-<50%), 4 = (50 -<70%), 5 = (70-<90%), 6 = (90-100%). Overall PASI = the sum of (individual scores x by a weighted factor for each body region).

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in PASI score in all subjects, including those on and those off therapy.

The PASI scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-<10%), 2 = (10-<30%), 3 = (30-<50%), 4 = (50 -<70%), 5 = (70-<90%), 6 = (90-100%). Overall PASI = the sum of (individual scores x by a weighted factor for each body region).

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses change from baseline in disease impact on daily activities, as measured by the DLQI, in all subjects including those on and those off therapy.

The DLQI is a 10-item PRO measure that assesses the extent to which the skin condition has affected the subject's quality of life over the past week, including 6 domains (daily activities, personal relationships, symptoms and feelings, leisure, work/school, and treatment). The total score (0-30) is the sum of 10 questions with each ranging from 0 to 3. The scoring of each question is as follows: Very much= 3, A lot=2, A little = 1, Not at all = 0, Not relevant = 0, Question unanswered = 0.

DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses % change from baseline in disease impact on daily activities, as measured by the DLQI, in all subjects including those on and those off therapy.

The DLQI is a 10-item PRO measure that assesses the extent to which the skin condition has affected the subject's quality of life over the past week, including 6 domains (daily activities, personal relationships, symptoms and feelings, leisure, work/school, and treatment). The total score (0-30) is the sum of 10 questions with each ranging from 0 to 3. The scoring of each question is as follows: Very much= 3, A lot=2, A little = 1, Not at all = 0, Not relevant = 0, Question unanswered = 0.

Subjects entering with a PGA = 0 had treatment discontinued. Subjects entering with a PGA ≥ 1 received tapinarof until they achieved a PGA = 0 and had treatment discontinued. If/when disease worsening (PGA ≥ 2) occurred treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study. The ITT population includes all subjects who signed the informed consent and enrolled in this extension study.